Long-Term Safety and Efficacy of Subcutaneous Cladribine Used in Increased Dosage in Patients with Relapsing Multiple Sclerosis: 20-Year Observational Study

Cladribine is currently registered as a 10-milligram tablet formulation with a fixed cumulative dosage of 3.5 mg/kg over 2 years. It is important to investigate if an increased dosage may lead to further clinical stability with preserved safety. This study used an off-label subcutaneous (s.c.) formu...

Descripción completa

Detalles Bibliográficos
Autores principales: Rejdak, Konrad, Zasybska, Adriana, Pietruczuk, Aleksandra, Baranowski, Dariusz, Szklener, Sebastian, Kaczmarek, Magda, Stelmasiak, Zbigniew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584572/
https://www.ncbi.nlm.nih.gov/pubmed/34768726
http://dx.doi.org/10.3390/jcm10215207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584572/
https://www.ncbi.nlm.nih.gov/pubmed/34768726
http://dx.doi.org/10.3390/jcm10215207

Ejemplares similares